A first-of-its-kind Alzheimer’s drug raises heavy questions around who will and won’t get it

Biogen priced its newly approved medicine Aduhelm at an average cost of $56,000 a year. Cigna, which estimates out-of-pocket costs may hit $10,000, is working on a value-based payment agreement with the drugmaker.